


<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 13615.40USU1		Application Number: 09/896,874
	Applicant: Beck ET AL.		
	Filing Date: JUNE 29, 2001	Group Art Unit: 16	



RECEIVED  
 DEC 19 2001  
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,224,179 (456)	09/23/1980	Schneider			
	4,231,877 (457)	11/04/1980	Yamauchi et al.			
	4,235,871 (447)	11/25/1980	Papahadjopoulos			
	4,247,411 (448)	01/27/1981	Vanlerberghe et al.			
	4,394,448 (458)	07/19/1983	Szoka, Jr. et al.			
	4,399,216 (459)	08/16/1983	Axel et al.			
	4,522,811 (707)	06/11/1985	Eppstein et al.			
	4,616,088 (688)	10/07/1986	Ryono et al.			
	4,636,491 (598)	01/13/1987	Bock et al.			
	4,665,193 (706)	05/12/1987	Ryono et al.			
	4,668,770 (99)	05/26/1987	Boger et al.			
	4,673,567 (460)	06/16/1987	Jizomoto			
	4,676,980 (461)	06/30/1987	Segal et al.			
	4,736,866 (474)	04/12/1988	Leder et al.			
	4,749,792 (597)	06/07/1988	Natarajan et al.			
	4,753,788 (462)	06/28/1988	Gamble			
	4,814,270 (463)	03/21/1989	Piran			
	4,816,567 (464)	03/28/1989	Cabilly et al.			
	4,870,009 (465)	09/26/1989	Evans et al.			
	4,880,781 (13)	11/14/1989	Hester, Jr. et al.			
	4,897,355 (466)	01/30/1990	Eppstein et al.			
	5,010,182 (467)	04/23/1991	Brake et al.			
	5,142,056 (590)	08/25/1992	Kempe et al.			
	5,145,684 (846)	09/08/1992	Liversidge et al.			
	5,162,538 (17)	11/10/1992	Voges et al.			
	5,175,281 (594)	12/29/1992	McCall et al.			
	5,250,565 (444)	10/05/1993	Brooks et al.			
U.S. PATENT DOCUMENTS						

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)			Docket Number: 13615.40USU1	Application Number: 09/896,874
			Applicant: Beck ET AL.	
	Filing Date: JUNE 29, 2001	Group Art Unit: 1614		


EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,364,934 (468)	11/15/1994	Drayna et al.			
	5,374,652 (446)	12/20/1994	Buzzetti et al.			
	5,376,542 (469)	12/27/1994	Schlegal			
	5,387,742 (177)	02/07/1995	Cordell			
	5,441,870 (189)	08/15/1995	Seubert et al.			
	5,461,067 (599)	10/24/1995	Norbeck et al.			
	5,475,138 (556)	12/12/1995	Pal et al.			
	5,481,011 (847)	01/02/1996	Chen et al.			
	5,482,947 (838)	01/09/1996	Talley et al.			
	5,502,061 (591)	03/26/1996	Hui et al.			
	5,502,187 (595)	03/26/1996	Ayer et al.			
	5,508,294 (837)	04/16/1996	Vazquez et al.			
	5,510,349 (853)	04/23/1996	Talley et al.			
	5,510,388 (703)	04/23/1996	Vazquez et al.			
	5,516,784 (640)	05/14/1996	Bennett et al.			
	5,521,219 (850)	05/28/1996	Vazquez et al.			
	5,545,640 (642)	08/13/1996	Beaulieu et al.			
	5,593,846 (201)	01/14/1997	Schenk et al.			
	5,602,175 (542)	02/11/1997	Talley et al.			
	5,602,169 (445)	02/11/1997	Hewawasam et al.			
	5,604,102 (202)	02/18/1997	McConlogue et al.			
	5,610,190 (638)	03/11/1997	Talley et al.			
	5,612,486 (185)	03/18/1997	McConlogue et al.			
	5,625,031 (470)	04/29/1997	Webster et al.			
	5,631,405 (554)	05/20/1997	Pal et al.			
	5,639,769 (836)	06/17/1997	Vazquez et al.			
	5,648,511 (704)	07/15/1997	Ng et al.			
	5,663,200 (18)	09/02/1997	Bold et al.			
	5,708,004 (536)	01/13/1998	Talley et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

TECH CENTER 1600/2900

DEC 19 2001

RECEIVED

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 13615.40USU1	Application Number: 09/896,874
	Applicant: Beck ET AL.	
	Filing Date: JUNE 29, 2001	Group Art Unit: 1614

	5,720,936 (186)	02/24/1998	Wadsworth et al.			
	5,721,130 (184)	02/24/1998	Seubert et al.			
	5,733,882 (29)	03/31/1998	Carr et al.			
	5,744,346 (182)	04/28/1998	Chrysler et al.			
	5,753,652 (711)	05/19/1998	Fässler et al.			
	5,760,064 (851)	06/02/1998	Vazquez et al.			
	5,760,076 (548)	06/02/1998	Vazquez et al.			
	5,766,846 (171)	06/16/1998	Schlossmacher et al.			
	5,807,870 (652)	09/15/1998	Anderson et al.			
	5,807,891 (19)	09/15/1998	Bold et al.			
	5,811,633 (176)	09/22/1998	Wadsworth et al.			
	5,827,891 (639)	10/27/1998	Dressman et al.			
	5,830,897 (653)	11/03/1998	Vazquez et al.			
	5,831,117 (547)	11/03/1998	Ng et al.			
	5,847,169 (645)	12/08/1998	Nummy et al.			
	5,849,911 (535)	12/15/1998	Fässler et al.			
	5,850,003 (705)	12/15/1998	McLonogue et al.			
	5,863,902 (428)	01/26/1999	Munoz et al.			
	5,872,101 (429)	02/16/1999	Munoz et al.			
	5,877,015 (710)	03/02/1999	Hardy et al.			
	5,877,399 (178)	03/02/1999	Hsiao et al.			
	5,912,410 (418)	06/15/1999	Cordell			
	5,922,770 (543)	07/13/1999	Peschke et al.			
	5,935,976 (91)	08/10/1999	Bold et al.			
	5,942,400 (181)	08/24/1999	Anderson et al.			
	5,962,419 (434)	10/05/1999	McDonald et al.			
	5,965,588 (686)	10/12/1999	Vazquez et al.			
	6,001,813 (131)	12/14/1999	Gyorkos et al.			
	6,013,658 (16)	01/11/2000	Lau et al.			
	6,022,872 (644)	02/08/2000	Vazquez et al.			
	6,045,829 (538)	04/04/2000	Liversidge et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 13615.40USU1	Application Number: 09/896,874
	Applicant: Beck ET AL.	
	Filing Date: JUNE 29, 2001	Group Art Unit: 161

	6,051,684 (427)	04/18/2000	McDonald et al.			
	6,060,476 (637)	05/09/2000	Vazquez et al.			
	6,150,344 (685)	11/21/2000.	Carroll et al.			
	6,153,652 (191)	11/28/2000	Wu et al.			
	6,191,166 B1 (50)	02/20/2001	Audia et al.			
	6,221,670 B1 (355)	04/24/2001	Cordell et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 036776 A2 (471)	09/30/1981	Europe				
	0 073 657 B1 (476)	03/09/1983	Europe				
	0 117 060 A2 (472)	08/29/1984	Europe				
	0 117 058 B1 (473)	08/29/1984	Europe				
	0 173 441 A1 (557)	05/03/1986	Europe				
	0 209 897 A2 (90)	01/28/1987	Europe				
	0 212 903 B1 (100)	03/04/1987	Europe				
	DE 3610593 A1 (98)	10/01/1987	Germany				
	0 264 106 B1 (101)	04/20/1988	Europe				
	DE 3721 855 A1 (93)	09/22/1988	Germany				
	0 274 259 A2 (89)	07/13/1988	Europe				
	2 203 740 A (544)	10/25/1988	UK				
	2 211 504 A (475)	07/05/1989	UK				
	0 320 205 A2 (102)	06/14/1989	Europe				
	0 337 714 (8)	10/18/1989	Europe				
	0 362 179 A2 (449)	04/04/1990	Europe				
	0 372 537 A2 (96)	06/13/1990	Europe				
	0 437 729 A2 (21)	07/24/1991	Europe				
	DE 40 03 575 A1	08/08/1991	Germany				
	0 609 625 A1 (567)	08/10/1994	Europe				
	0 652 009 A1 (709)	05/10/1995	Europe				
	7-126286 (97)	05/16/1995	Japan				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)				Docket Number: 13615.40USU1		Application Number: 09/896,874	
				Applicant: Beck ET AL.			
				Filing Date: JUNE 29, 2001		Group Art Unit: 16	


	WO 87/02986 (551)	05/21/1987	PCT				
	WO 87/04349 (10)	07/30/1987	PCT				
	WO 87/05330 (454)	09/11/1987	PCT				
	WO 89/00161 (15)	01/12/1989	PCT				
	WO 89/01488 (12)	02/23/1989	PCT				
	WO 89/05859 (453)	06/29/1989	PCT				
	WO 90/13646 (452)	11/15/1990	PCT				
	WO 91/00360 (451)	01/10/1991	PCT				
	WO 92/00750 (537)	01/23/1992	PCT				
	WO 92/17490 (14)	10/15/1992	PCT				
	WO 92/20373 (455)	11/26/1992	PCT				
	WO 93/02057 (11)	02/04/1993	PCT				
	WO 93/08829 (450)	05/13/1993	PCT				
	WO 93/17003 (7)	09/02/1993	PCT				
	WO 94/04492 (848)	03/03/1994	PCT				
	WO 95/06030 (839)	03/02/1995	PCT				
	WO 97/30072 (22)	08/21/1997	PCT				
	WO 98/22597 (170)	05/28/1998	PCT				
	WO 98/29401 (562)	07/09/1998	PCT				
	WO 98/33795 (546)	08/06/1998	PCT				
	WO 98/50342 (550)	11/12/1998	PCT				
	WO 99/41266 (568)	08/19/1999	PCT				
	WO 99/54293 (635)	10/28/1999	PCT				
	WO 00/17369 (169)	03/30/2000	PCT				
	WO 00/47618 (364)	08/17/2000	PCT				
	WO 00/56335 (314)	09/28/2000	PCT				
	WO 00/61748 (302)	10/19/2000	PCT				
	WO 00/69262 (272)	11/23/2000	PCT				
	WO 00/77030 (256)	12/21/2000	PCT				
	WO 01/00663 (159)	01/04/2001	PCT				
	WO 01/00665 A2 (20)	01/04/2001	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

RECEIVED  
 DEC 19 2001  
 TECH CENTER 1600/2900


<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 13615.40USU1	Application Number: 09/896,874
	Applicant: Beck ET AL.	
	Filing Date: JUNE 29, 2001	Group Art Unit: 1614

	WO 01/10387 A2 (443)	02/15/2001	PCT				
	WO 01/19797 A2 (381)	03/22/2001	PCT				
	WO 01/23533 A2 (289)	04/05/2001	PCT				
	WO 01/29563 A1 (479)	04/26/2001	PCT				
	WO 01/51659 A2 (790)	07/19/2001	PCT				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)


	Abbenante, et al., <i>Biochemical and Biophysical Research Communications</i> , 2000, 268, pp. 133135 Inhibitors of $\beta$ -Amyloid Formation Based on the $\beta$ -Secretase Cleavage Site [439]
	Alterman et al., <i>J. Med. Chem.</i> , 1998, 41, 3782-3792 Design and Synthesis of New Potent C <sub>2</sub> -Symmetric HIV-1 Protease Inhibitors. Use of L-Mannaric Acid as a Peptidomimetic Scaffold [868]
	Amblard et al., <i>J. Med. Chem.</i> , 1999, 42:20, pp. 4193-4201 Synthesis and Characterization of Bradykinin B <sub>2</sub> Receptor Agonists Containing Constrained Dipeptide Mimics [730]
	Arrowsmith et al., <i>Tetrahedron Letters</i> , 1987, 28:45, pp. 5569-5572 Amino-Alcohol Dipeptide Analogues: A Simple Synthesis of a Versatile Isostere for the Development of Proteinase Inhibitors [584]
	Askin et al., <i>The Journal of Organic Chemistry</i> , 1992, 57:10, pp. 2771-2773 Highly Disastrous Alkylations of Chiral Amide Enolates: New Routes to Hydroxyethylene Dipeptide Isostere Inhibitors of HIV-1 Protease [561]
	Balicki et al., <i>Synth. Comm.</i> , 1993, 23(22), pp. 3149-3155 Mild and Efficient Conversion of Nitriles to Amides with Basic Urea-Hydrogen Peroxide Adduct [874]
	Barton, <i>Protective Groups in Organic Chemistry</i> , 1976, Chpt. 2, pp. 43-93 Protection of N-H Bonds and NR <sub>3</sub> [718]
	Basu et al., <i>Tetrahedron Letters</i> , 1998, 39, pp. 3005-3006 Efficient Transformation of Nitrile into Amide under Mild Condition [881]
	Bennett et al., <i>Synlett</i> , 1993, 9, pp. 703-704 The Synthesis of Novel HIV-Protease Inhibitors via Silica Gel Assisted Addition of Amines to Epoxides [744]
	Berge et al., <i>Journal of Pharmaceutical Sciences</i> , 1/1977, 66:1, pp. 1-19 Pharmaceutical Salts [735]
	Blatt, <i>Organic Syntheses</i> , Collective Vol. 2, pp. 312-315 Heptaldoxime [883]
	Bodendorf et al., <i>The Journal of Biological Chemistry</i> , 2001, 276:15, pp. 12019 - 12023 A Splice Variant of $\beta$ -Secretase Deficient in the Amyloidogenic Processing of the Amyloid Precursor Protein [493]

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449*  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 13615.40USU1	Application Number: 09/896,874
	Applicant: Beck ET AL.	
	Filing Date: JUNE 29, 2001	Group Art Unit: 1614

		Bose et al., <i>Synth. Comm.</i> , 1997, 27(18), pp. 3119 - 3123 A Facile Hydration of Nitriles by Dimethyldioxirane [ 876]
		Calderwood et al., <i>Tetrahedron Letters</i> , 1997, 38:7, pp. 1241 - 1244 Organocerium Reactions of Benzamides and Thiobenzamides: A Direct Synthesis of Tertiary Carbinamines [741]
		Chen et al., <i>Tetrahedron -Mannaric Acid Letters</i> , 1997, 38:18, pp. 3175 - 3178 A Practical Method for the Preparation of $\alpha'$ -Chloroketones of N-Carbamate Protected- $\alpha$ -Aminoacids [885]
		Ciganek, <i>J. Org. Chem.</i> , 1992, 57:16, pp. 4521 - 4527 Tertiary Carbinamines by Addition of Organocerium Reagents to Nitriles and Ketimines [721]
		Citron et al., <i>Nature</i> , 1992, 360:6405, pp. 672-674 Mutation of the $\beta$ -amyloid Precursor Protein in Familial Alzheimer's Disease Increases $\beta$ -Protein Production [722]
		Cushman et al., <i>J. Med. Chem.</i> , 1997, 40:15, pp. 2323 - 2331 Synthesis of Analogs of 2-Methoxyestradiol with Enhanced Inhibitory Effects on Tubulin Polymerization and Cancer Cell Growth [734]
		Deno, et al., <i>J. Am. Chem. Soc.</i> , 1970, 92:7, pp. 3700 - 3703 Protonated Cyclopropane Intermediates in the Reactions of Cyclopropanecarboxylic Acids [727]
		Diedrich et al., <i>Tetrahedron Letters</i> , 1993, 34:39, pp. 6169-6172 Stereoselective Synthesis of A Hydroxyethylene Dipeptide Isostere [559]
		Diercks et al., <i>J. Am. Chem. Soc.</i> , 1986, 108:11, pp. 3150-3152 Tris(benzocyclobutadieno)benzene, the Triangular [4]Phenylene with a Completely Bond-Fixed Cyclohexatriene Ring: Cobalt-Catalyzed Synthesis from Hexaethynylbenzene and Thermal Ring Opening to 1,2:5,6:9, 10-Tribenzo-3,4,7,8,11,12 hexadehydro[12]-annulene [728]
		Dovey et al., <i>Journal of Neurochemistry</i> , 2001, 76, pp. 173-181 Functional Gamma-Secretase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain [396]
		Dragovich et al., <i>Journal of Medicinal Chemistry</i> , 1999, 42:7, pp. 1203-1212 Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors [553]
		Emilien, et al., <i>Neurological Review</i> , 2000, 57, pp. 454-459 Prospects for Pharmacological Intervention in Alzheimer Disease [723]
		Felman et al., <i>J. Med. Chem.</i> 1992, 35:7, pp. 1183-1190 Synthesis and Antiulcer Activity of Novel 5-(2-Ethenyl Substituted)-3(2H)furanones [724]
		Games et al., <i>Letters to Nature</i> , 2/9/1995, 373:6514, pp. 523-527 Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F $\beta$ -amyloid Precursor Protein [441]
		Gao et al., <i>Tetrahedron Letters</i> , 1994, 50:4, pp. 979-988 Asymmetric Hetero Diels-Alder Reaction Catalyzed by Stable and Easily Prepared CAB Catalysts [882]
		Getman et al., <i>J. Med. Chem.</i> , 1993, 36:2, pp. 288-291 Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere [732]
		Ghosh et al., <i>J. Am. Chem. Soc.</i> , 2000, 122, pp. 3522-3523 Design of Potent Inhibitors for Human Brain Memapsin 2 ( $\beta$ -Secretase). [588]
		Ghosh et al., <i>J. Med. Chem.</i> , 1993, 36, pp. 2300-2310


EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 13615.40USU1	Application Number: 09/896,874
	Applicant: Beck ET AL.	
	Filing Date: JUNE 29, 2001	Group Art Unit: 1614

	Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel P <sub>2</sub> -Ligands [869]
	Gould, <i>International Journal of Pharmaceutics</i> , 1986, 33:1-3, pp. 201 - 217 Salt Selection for Basic Drugs [566]
	Greene et al., <i>Protective Groups in Organic Synthesis: 2nd Ed.</i> , 1991, Chpt. 7, pp. 309-405 Protection for the Amino Group [747]
	Greene, <i>Protective Groups in Organic Synthesis</i> , 1981, Chpt. 7, pp.218-287 Protection for the Amino Group [719]
	Hardy, <i>Nature Genetics</i> , 1992, 1, pp. 233-234 Framing $\beta$ -Amyloid [725]
	Heck, <i>Palladium Reagents in Organic Syntheses</i> , 1985, Chpt. 8.2, pp. 342-365 Carbonylation of Aromatic Compounds to Acids, Acid Derivatives, Aldehydes and Ketones [870]
	Henning, <i>Organic Synthesis Highlights II</i> , 1995, pp. 251 - 259 A. Synthetic Routes to Different Classes of Natural Products and Analogs Thereof -- Synthesis of Hydroxyethylene Isoteric Dipeptides [565]
	Hon et al., <i>Heterocycles</i> , 1990, 31:10, pp. 1745-1750 The Studies of Metal Ion Catalyzed Carbon-Hydrogen Insertion of $\alpha$ -Alkoxy- $\alpha'$ -Diazoketones Derived from Mandelic and Lactic Acids [539]
	Hong et al., <i>Science</i> , 2000, 290:5489, pp. 150-153 Structure of the Protease Domain of Memapsin 2 ( $\beta$ -Secretase) Complexed with Inhibitor [440]
	Hussain et al., <i>Molecular and Cellular Neuroscience</i> , 1999, 14, pp. 419-427 Identification of a Novel Aspartic Protease (Asp 2) as $\beta$ -Secretase [726]
	Kabalka et al., <i>Synth. Comm.</i> , 1990, 20(10), pp. 1445-1451 The Transformation of Nitriles into Amides [875]
	Kaldor et al., <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5:7, pp. 721-726 Isophthalic Acid Derivatives: Amino Acid Surrogates for the Inhibition of HIV-1 Protease [587]
	Kang et al., <i>Nature</i> , 1987, 325:6106, pp. 733-736 The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor [505]
	Kitaguchi et al., <i>Nature</i> , 2/11/1988, 331:6156, pp. 530-532 Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity [736]
	Klumpp et al., <i>J. Am. Chem. Soc.</i> , 1979, 101:23 Lithiation of Cyclopropylcarbinols [871]
	Lakouraj et al., <i>Indian Journal of Chemistry</i> , 1999, 38B, pp. 974-975 Selective Conversion of Nitriles to Amides by Amberlyst A-26 Supported Hydroperoxide [879]
	Larock, <i>Comprehensive Organic Transformations</i> , 1986, Chpt 4, pp. 972-985 Carboxylic Acids to Amides [555]
	Li et al., <i>Nature</i> , 2000, 405, pp. 689-694 Photoactivated V-secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1 [24]
	Li et al., <i>Nature</i> , 2000, 405:6787, pp. 689-694

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	



<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 13615.40USU1	Application Number: 09/896,874
	Applicant: Beck ET AL.	
	Filing Date: JUNE 29, 2001	Group Art Unit: 1614

	Photoactivated Gamma-Secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1. [585]
	Lin et al., <i>PNAS</i> , 2000, 97:4, pp. 1456-1460 Human Aspartic Protease Memapsin 2 Cleaves the $\beta$ -Amyloid Precursor Protein [687]
	Luly et al., <i>Journal of Organic Chemistry</i> , 1987, 52:8, pp. 1487-1492 A Synthesis of Protected Aminoalkyl Epoxides from Alpha Amino Acids [558]
	Luo et al., <i>Nature Neuroscience</i> , 3/2001, 4:3, pp. 231-232 Mice Deficient in BACE1, the Alzheimer's $\beta$ -secretase, have Normal Phenotype and Abolished $\beta$ -amyloid Generation [210]
	March, <i>Advanced Organic Chemistry: Reactions, Mechanisms, and Structure</i> , 3d Ed., pp. 380-381 Aliphatic Nucleophilic Substitution [729]
	Martin et al., <i>Tetrahedron Letters</i> , 1998, 39, pp. 1517-1520 Application of Almez-Mediated Amidation Reactions to Solution Phase Peptide Synthesis [540]
	Mashraqui et al., <i>J. Am. Chem. Soc.</i> , 1982, 104, pp. 4461-4465 Cyclophanes. 14. Synthesis, Structure Assignment, and Conformational Properties of [2.2](2,5)Oxazolo- and Thiazolophanes [872]
	McLendon et al., <i>The FASEB Journal</i> , 2000, 14:15, pp. 2383-2386 Cell-Free Assays for Gamma-Secretase Activity [359]
	Miyaura et al., <i>Chem. Rev.</i> , 1995, 95, pp. 2457-2483 Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds [720]
	Moersch et al., <i>Synthesis</i> , 1971, 12, pp. 647-649 The Synthesis of Alpha-Hydroxycarboxylic Acids by Aeration of Lithiated Carboxylic Acids in Tetrahydrofuran Solution [564]
	Murahashi et al., <i>J. Org. Chem.</i> , 1992, 57:9, pp. 2521-2523 Ruthenium-Catalyzed Hydration of Nitriles and Transformation of $\delta$ -Keto Nitriles to Ene-Lactams [877]
	Norman et al., <i>J. Med. Chem.</i> , 2000, 43, pp. 4288-4312 Structure-Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine Derivatives and Related Compounds as Neuropeptide Y5 Receptor Antagonists [867]
	Owa et al., <i>J. Med. Chem.</i> , 1999, 42, pp. 3789-3799 Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle [866]
	Pirttila et al., <i>Neuroscience Letter</i> , 1998, 249, pp. 21-24 Longitudinal Study of Cerebrospinal Fluid Amyloid Proteins and Apolipoprotein E in Patients with Probable Alzheimer's Disease [738]
	Reetz et al., <i>Tetrahedron Letters</i> , 30:40, pp. 5425-5428 Protective Group Tuning in the Stereoselective Conversion of $\alpha$ -Amino Aldehydes into Aminoalkyl Epoxides [884]
	Sabbagh et al., <i>Alzheimer's Disease Review</i> , 1997, 3, 1-19 $\beta$ -Amyloid and Treatment Opportunities for Alzheimer's Disease [589]
	Sakurai et al., <i>Chemical &amp; Pharmaceutical Bulletin</i> , 1993, 41:8, pp. 1378-1386 Studies of HIV-1 Protease Inhibitors, II, Incorporation of Four Types of Hydroxyethylene Dipeptide Isosteres at the Scissile Site of Substrate Sequences [549]
	Sakurai et al., <i>Tetrahedron Letters</i> , 1993, 34:10, pp. 5939-5942 A New Synthetic Route for the Gamma-Lactone Precursors of Hydroxyethylene Dipeptide Isosteres [563]

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

RECEIVED  
 DEC 19 2001  
 TECH CENTER 160012900

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)		Docket Number: 13615.40USU1	Application Number: 09/896,874
		Applicant: Beck ET AL.	
		Filing Date: JUNE 29, 2001	Group Art Unit: 16

	Sebti et al., <i>Tetrahedron Letters</i> , 1996, 37:36, pp. 6555-6556 Catalyse Heterogene de L'Hydratation des Nitriles en Amides par le Phosphate Naturel Dope par KF et le Phosphate Trisodique [878]
	Selkoe, <i>Nature</i> , 1999, 399:6738, pp. A23-A31 Translating Cell Biology into Therapeutic Advances in Alzheimer's Disease [541]
	Selkoe, <i>Neuron</i> , 1991, 6:4, pp. 487-498 The Molecular Pathology of Alzheimer's Disease [742]
	Seubert, et al., <i>Nature</i> , 9/1992, 359:6393, pp. 325327 Isolation and Quantification of Soluble Alzheimer's $\beta$ -peptide from Biological Fluids [503]
	Shearman et al., <i>Biochemistry</i> , 2000, 39, pp. 8698-9704 L-685, 458, an Aspartyl Protease Transition State Mimic, is a Potent Inhibitor of Amyloid $\beta$ -Protein Precursor $\gamma$ -Secretase Activity [394]
	Shibata et al., <i>Tetrahedron Letters</i> , 1997, 38:4, pp. 619-620 An Expeditious Synthesis of (2R,3S)-3- <i>tert</i> -Butoxycarbonylamino-1-isobutylamino-4-phenyl-2-butanol, a Key Building Block of HIV Protease Inhibitors [583]
	Sinha, et al., <i>Nature</i> , 12/2/1999, 402:6761, pp. 537540 Purification and Cloning of Amyloid Precursor Protein $\beta$ -secretase from Human Brain [743]
	Smith et al., <i>Advanced Organic Chemistry - Reactions, Mechanisms and Structure</i> , 2001, 5ed., Chpt. 19, pp. 1552-1554 Reduction of Carboxylic Acids and Esters to Alkanes [919]
	Snyder et al., <i>J. Am. Chem. Soc.</i> , Jan - Jun 1938, pp. 105-111 Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids [873]
	Thurkauf et al., <i>J. Med. Chem.</i> , 1990, 33, 1452-1458 Synthesis and Anticonvulsant Activity of 1-Phenylcyclohexylamine Analogues [749]
	Tucker et al., <i>J. Med. Chem.</i> , 1992, 35:14, pp. 2525-2533 A Series of Potent HIV-1 Protease Inhibitors Containing a Hydroxyethyl Secondary Amine Transition State Isostere: Synthesis, Enzyme Inhibition, and Antiviral Activity [731]
	Vassar et al., <i>Science</i> , 10/22/1999, 286:5440, pp. 735-741 $\beta$ -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE [750]
	Vazquez et al., <i>J. of Med. Chem.</i> , 1995, 38:4, pp. 581-584 Inhibitors of HIV-1 Protease Containing the Novel and Potent $\alpha$ -Hydroxyethyl)sulfonamide Isostere [582]
	Wang et al., <i>Synlett</i> , 6/2000, 6, pp. 902-904 Preparation of $\alpha$ -Chloroketones by the Chloroacetate Claisen Reaction [886]
	Werner et al., <i>Organic Syntheses</i> , 1973, Collective Vol. 5, pp. 273-276 Cyclobutylamine* [752]
	Wilgus, et al., <i>Tetrahedron Letters</i> , 1995, 36:20, pp. 3469-3472 The Acid-Catalyzed and Uncatalyzed Hydrolysis of Nitriles on Unactivated Alumina [880]
	Yan et al., <i>Nature</i> , 12/1999, 402:6761, pp. 533-537 Membrane-anchored Aspartyl Protease with Alzheimer's Disease $\beta$ -secretase Activity [753]

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 13615.40USU1	Application Number: 09/896,874
	Applicant: Beck ET AL.	
	Filing Date: JUNE 29, 2001	Group Art Unit: 1614




EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	